122684-35-9 Usage
Uses
Used in Pharmaceutical Production:
3-Thiocarbamoyl-pyrrolidine-1-carboxylic Acid Tert-Butyl Ester is used as an intermediate compound for alkaloid synthesis, which is common in the production of pharmaceuticals. Its presence in this process is due to the pyrrolidine component, which is often found in alkaloid structures.
Used in Chemical Reactions:
In laboratory or industrial settings, 3-Thiocarbamoyl-pyrrolidine-1-carboxylic Acid Tert-Butyl Ester is used as a reactant in larger chemical reactions. Its thiocarbamoyl portion indicates that it may be involved in the creation of other sulfonyl-related compounds, which are important in various chemical processes.
Used in Sulfonyl Compound Synthesis:
3-Thiocarbamoyl-pyrrolidine-1-carboxylic Acid Tert-Butyl Ester is used as a precursor in the synthesis of sulfonyl compounds. Its sulfur properties make it a valuable component in the production of these compounds, which have various applications in different industries.
Note: Due to the lack of specific data regarding the direct applications of 3-THIOCARBAMOYL-PYRROLIDINE-1-CARBOXYLIC ACID TERT-BUTYL ESTER, the uses listed above are based on the chemical properties and typical uses of similar compounds. It is important to consult with experts or conduct further research to determine the exact applications of 3-Thiocarbamoyl-pyrrolidine-1-carboxylic Acid Tert-Butyl Ester.
Check Digit Verification of cas no
The CAS Registry Mumber 122684-35-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,2,6,8 and 4 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 122684-35:
(8*1)+(7*2)+(6*2)+(5*6)+(4*8)+(3*4)+(2*3)+(1*5)=119
119 % 10 = 9
So 122684-35-9 is a valid CAS Registry Number.
InChI:InChI=1/C10H18N2O2S/c1-10(2,3)14-9(13)12-5-4-7(6-12)8(11)15/h7H,4-6H2,1-3H3,(H2,11,15)
122684-35-9Relevant academic research and scientific papers
NOVEL FERROPORTIN INHIBITORS
-
Page/Page column 231, (2017/05/10)
The invention relates to novel ferroportin inhibitors of the general formula (I) pharmaceutical compositions comprising them and the use thereof as medicaments, in particular for the prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, such as particularly iron overload states such as in particular thalassemia and hemochromatosis.
SUBSTITUTED NICOTINIMIDE INHIBITORS OF BTK AND THEIR PREPARATION AND USE IN THE TREATMENT OF CANCER, INFLAMMATION AND AUTOIMMUNE DISEASE
-
Page/Page column 91, (2015/04/15)
Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR
-
Page/Page column 23, (2008/06/13)
The present invention relates to novel fused thiazole derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.
Synthesis and muscarinic activities of 1,2,4-thiadiazoles
MacLeod,Baker,Freedman,Patel,Merchant,Roe,Saunders
, p. 2052 - 2059 (2007/10/02)
A series of novel 1,2,4-thiadiazoles bearing a mono- or bicyclic amine at C5 were prepared. Quinuclidine and 1-azabicyclo[2.2.1]heptane derivatives were synthesized by reaction of the lithium enolate of the 3-methoxycarbonyl compounds followed by ester hy
